Immunotoxins
Research News and Information

Sunday, November 22, 2009

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

4 Oct 2009 BACKGROUND: Potency, immunogenicity, and toxicity are three problems that limit the use of targeted toxins in solid tumour therapy. METHODS: To address potency, we used genetic engineering to develop a novel bispecific ligand-directed toxin (BLT) ... Read more...

Nitrous oxide-induced analgesia does not influence nitrous oxide's immobilizing requirements.

29 Sep 2009 BACKGROUND: Nitrous oxide (N(2)O) acts on supraspinal noradrenergic neurons to produce analgesia, but it is unclear if analgesia contributes to N(2)O's immobilizing effects. We tested the hypothesis that N(2)O minimum alveolar anesthetic ... Read more...

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo.

20 Sep 2009 BACKGROUND: The clinical use of immunotoxins (ITs) has been hampered by hepatotoxicity, and the induction of a strong human-anti-IT response. The human-anti-IT response results in neutralisation of the immunoconjugates, rendering repetitive ... Read more...

Latest indexed articles for 'Immunotoxins'

These are the very latest articles for this heading:

• Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. 4 Oct 2009
• Nitrous oxide-induced analgesia does not influence nitrous oxide's immobilizing requirements. 29 Sep 2009
• Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. 20 Sep 2009
• Immunotoxin-induced ablation of melanopsin retinal ganglion cells in a non-murine mammalian model. 8 Sep 2009
• Inhibition of tumor growth by targeted toxins in mice is dramatically improved by saponinum album in a synergistic way. 30 Aug 2009
• The neurokinin-1 receptor modulates the methamphetamine-induced striatal apoptosis and nitric oxide formation in mice. 11 Aug 2009
• A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma. 30 Jul 2009
• Immunotoxic depletion of microglia in mouse hippocampal slice cultures enhances ischemia-like neurodegeneration. 8 Jul 2009
• Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. 29 Jun 2009
• Novel drug delivery strategies in neuro-oncology. 29 Jun 2009
• The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cells in vitro. 29 Jun 2009
• Evaluation of nanoparticle immunotoxicity. 26 Jun 2009
• A cholinergic-dependent role for the entorhinal cortex in trace fear conditioning. 22 Jun 2009
• Toward an effective targeted chemotherapy for multiple myeloma. 7 Jun 2009
• The pharmacologic basis for antibody-auristatin conjugate activity. 2 Jun 2009
• Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy. 31 May 2009
• Listeriolysin O as cytotoxic component of an immunotoxin. 30 May 2009
• Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. 17 May 2009
• Cancer therapy using tumor-associated antigens to reduce side effects. 29 Apr 2009
• Effects of chronic donepezil treatment and cholinergic deafferentation on parietal pyramidal neuron morphology. 29 Apr 2009

See a longer list of these articles.

Technical information about 'Immunotoxins'

Definition: Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant TOXINS, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.

Registry Number: 0

Descriptor UI: D000922

Alternative terms: Immunotoxins; Antibody-Toxin Conjugates; Antibody Toxin Conjugates; Conjugates, Antibody-Toxin; Antibody-Toxin Hybrids; Antibody Toxin Hybrids; Hybrids, Antibody-Toxin; Cytotoxin-Antibody Conjugates; Conjugates, Cytotoxin-Antibody; Cytotoxin Antibody Conjugates; Monoclonal Antibody-Toxin Conjugates; Antibody-Toxin Conjugates, Monoclonal; Conjugates, Monoclonal Antibody-Toxin; Monoclonal Antibody Toxin Conjugates; Toxin-Antibody Conjugates; Conjugates, Toxin-Antibody; Toxin Antibody Conjugates; Toxin-Antibody Hybrids; Hybrids, Toxin-Antibody; Toxin Antibody Hybrids; Affinotoxins; Immunotoxin; Toxins, Chimeric; Chimeric Toxins; Toxin Conjugates; Conjugates, Toxin; Toxin Carriers; Carriers, Toxin; Toxin Conjugate; Conjugate, Toxin; Chimeric Toxin; Toxin, Chimeric; Toxin Carrier; Carrier, Toxin; Targeted Toxins; Toxins, Targeted;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; classification; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacology; poisoning; radiation effects; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; pharmacokinetics;

Pharmacological Action: Immunologic Factors;

Tree Number: D12.776.124.486.485.114.580.450; D12.776.124.790.651.114.580.450; D12.776.377.715.548.114.580.450; D27.888.569.271;

Online Note: use IMMUNOTOXINS to search ANTIBODY-TOXIN CONJUGATES 1987-89

History Note: 90; was ANTIBODY-TOXIN CONJUGATES 1987-89

Technical Notes: coordinate IM with specific toxin (IM) + specific immune substance (NIM)